

would request from commenters, as part of such a proceeding.

FOR FURTHER INFORMATION CONTACT:

Arija Flowers, Trial Attorney, Office of the Chief Counsel, NCC-111, National Highway Traffic Safety Administration, 1200 New Jersey Avenue SE., Washington, DC 20590 (telephone: 202-366-8714).

SUPPLEMENTARY INFORMATION: In order to ensure that all vehicles in the United States are equipped with safe air bags as quickly as possible and to reduce the risk of serious injury or death due to an inflator rupture, NHTSA is considering exercising its authority under the National Traffic and Motor Vehicle Safety Act of 1966, as amended and recodified (the “Safety Act”), 49 U.S.C. 30101, *et seq.*, to organize and prioritize the remedy programs of BMW of North America, LLC (“BMW”), Chrysler Group, LLC (“Chrysler”), Daimler Trucks North America, LLC (“DTNA”), Ford Motor Company (“Ford”), General Motors, LLC (“GM”), American Honda Motor Company (“Honda”), Mazda North American Operations (“Mazda”), Mitsubishi Motors North America, Inc. (“Mitsubishi”), Nissan North America, Inc. (“Nissan”), Subaru of America, Inc. (“Subaru”), and Toyota Motor Engineering and Manufacturing (“Toyota”) (collectively, the “Manufacturers”), and TK Holdings, Inc. (“Takata”) to address Takata frontal air bag inflators. Specifically, NHTSA is issuing this notice pursuant to its authority under the Safety Act to “accelerate” a remedy program, 49 U.S.C. 30120(c)(3) and 49 CFR 573.14, as delegated by the Secretary of Transportation, 49 CFR 1.95, 501.2(a)(1), to inspect and investigate, 49 U.S.C. 30166(b)(1), and to ensure that defective vehicles and equipment are recalled, 49 U.S.C. 30118–30119.

On May 18, 2015, Takata filed four Defect Information Reports (“DIR’s”) pursuant to 49 CFR 573.6. In those DIR’s, Takata determined that a defect exists in certain models of frontal air bag inflators (PSDI, PSDI-4, PSDI-4K, SPI, PSPI and PSPI-L).

The Safety Act requires manufacturers to remedy safety-related defects in motor vehicles. 49 U.S.C. 30120(a). If the Secretary of Transportation determines that a manufacturer’s remedy program is not likely to be capable of completion within a reasonable time, the Secretary may require the manufacturer to “accelerate” the remedy program if the Secretary finds that there is a risk of serious injury or death if the remedy program is not accelerated and that acceleration of the remedy program can be reasonably

achieved by expanding the sources of replacement parts, expanding the number of authorized repair facilities, or both. *Id.* § 30120(c)(3). The Secretary has delegated his authorities under the Safety Act to the NHTSA Administrator, 49 CFR 1.95(a), 501.2(a)(1). Each of the Manufacturers has elected a remedy program of repair of the affected vehicles. *See* 49 U.S.C. 30120(a)(1)(A). These remedy programs are individual to each of the Manufacturers, creating a patch-work solution that NHTSA believes may not adequately address the safety risks presented by the defective Takata inflators within a reasonable time. Regardless of root cause, these recalls involve the same safety risk: The risk of the air bag inflator rupturing when the air bag is inflated, which may result in serious injury or death to vehicle occupants without any prior warning.

The number of impacted vehicles and manufacturers in combination with the supply issues related to these air bag recalls adds a previously unprecedented level of complexity to this recall and remedy process. Given the number of manufacturers (11) and the technical complexity of the issues involved, NHTSA intends to open a Section 30120(c)(3) proceeding, and has therefore issued this Notice of Intent to inform the public.

The goal of a Section 30120(c)(3) proceeding is for the agency to consider whether (and if so, how) to organize and prioritize the recall and remedy programs of the Manufacturers, in order to aid the Manufacturers in accomplishing their significant task of replacing all defective Takata air bag inflators.

As part of a Section 30120(c)(3) proceeding, NHTSA plans to consider the views of commenters regarding NHTSA’s exercising its authority with respect to recall and remedy programs involving certain defective Takata frontal air bag inflators, including, but not limited to whether it should, and on what terms, issue an order to “accelerate” all applicable recall remedy programs, which could include, but not be limited to, provisions regarding sourcing, production, allocation, delivery, installation, and adequacy of the remedy.

Further, as part of a Section 30120(c)(3) proceeding, NHTSA would specifically request comments on how the Manufacturers would comply with an organization and prioritization of remedy directive, the possible terms of any such order and, in particular, how NHTSA should order the sourcing of the replacement parts for Manufacturers, whether NHTSA should issue the

remedy order to some but not all Manufacturers, whether NHTSA should order the Manufacturers to prioritize certain vehicles or certain regions in its allocation of replacement parts and how, and whether NHTSA should order a re-replacement schedule for replacement frontal inflators if Takata cannot provide assurances for the ongoing safety of the inflators.

Upon NHTSA’s opening of a Section 30120(c)(3) proceeding, additional information, including how to comment, will be published in a supplemental **Federal Register** Notice.

Authority: 49 U.S.C. 30101, *et seq.*, 30118–30119, 30120(c)(3), 30166(b)(1); 49 CFR 573.6, 573.14; delegations of authority at 49 CFR 1.95(a), 501.2(a)(1).

Issued: May 18, 2015.

Mark R. Rosekind,
Administrator

[FR Doc. 2015–12449 Filed 5–21–15; 8:45 am]

BILLING CODE 4910–59–P

DEPARTMENT OF THE TREASURY

Office of the Comptroller of the Currency

[OCC Charter Number 706335]

St. James Federal Savings and Loan Association, St. James, Minnesota; Approval of Conversion Application

Notice is hereby given that on May 14, 2015, the Office of the Comptroller of the Currency (OCC) approved the application of St. James Federal Savings and Loan Association, St. James, Minnesota, to convert to the stock form of organization. Copies of the application are available for inspection on the OCC Web site at the FOIA Electronic Reading Room <https://foia-pal.occ.gov/palMain.aspx>. If you have any questions, please call OCC Licensing Activities at (202) 649–6260.

Dated: May 14, 2014.

By the Office of the Comptroller of the Currency.

Stephen A. Lybarger,
Deputy Comptroller for Licensing.

[FR Doc. 2015–12395 Filed 5–21–15; 8:45 am]

BILLING CODE 4810–33–P

DEPARTMENT OF VETERANS AFFAIRS

[OMB Control No. 2900–0085]

Agency Information Collection (Appeal to Board of Veterans’ Appeals) Activity Under OMB Review

AGENCY: Board of Veterans’ Appeals, Department of Veterans Affairs.

ACTION: Notice; correction

SUMMARY: The Department of Veterans Affairs (VA) published a collection of information notice in a **Federal Register** February 19, 2015, that contained an error. The notice incorrectly stated the agency as “Office of Acquisition, Logistics and Construction, Department of Veterans Affairs.” This document corrects the error by correcting the name of the agency.

FOR FURTHER INFORMATION CONTACT: Crystal Rennie, Enterprise Records Service (005R1B), Department of Veterans Affairs, 810 Vermont Avenue NW., Washington, DC 20420, at 202–632–7492.

Correction

In FR Doc. 2015–03425, published on February 19, 2015, at 80 FR 8952 make the following correction. On page 8952, at the top of the page, the name of the agency should read as follows:

AGENCY: Board of Veterans’ Appeals, Department of Veterans Affairs.

By direction of the Secretary.

Crystal Rennie,

Department Clearance Officer, Department of Veterans Affairs.

[FR Doc. 2015–12369 Filed 5–21–15; 8:45 am]

BILLING CODE 8320–01–P

DEPARTMENT OF VETERANS AFFAIRS

Research Advisory Committee on Gulf War Veterans’ Illnesses; Notice of Meeting

The Department of Veterans Affairs (VA) gives notice under the Federal Advisory Committee Act, 5 U.S.C. App. 2 that the Research Advisory Committee on Gulf War Veterans’ Illnesses will meet on June 23, 2015, in Washington, DC. The meeting will be held in Room 230, 810 Vermont Avenue NW., Washington, DC, from 9:00 a.m. until 5:30 p.m. All sessions will be open to the public. Interested persons who cannot attend the meeting may use this toll-free telephone number (800) 767–

1750; access code 56978# to listen to the meeting.

The purpose of the Committee is to provide advice and make recommendations to the Secretary of Veterans Affairs on proposed research studies, research plans, and research strategies relating to the health consequences of military service in the Southwest Asia Theater of operations during the Gulf War in 1990–1991.

The Committee will review VA program activities related to Gulf War Veterans’ Illnesses, and receive updates on relevant scientific research published since the last Committee meeting. Presentations will include updates on the VA Gulf War Research Program, followed by research presentations describing treatments and treatment research involving Gulf War Veterans. There will also be a discussion of Committee business and activities.

The meeting will include time reserved for public comments in the afternoon. A sign-up sheet for 5-minute comments will be available at the meeting. Individuals who wish to address the Committee may submit a 1–2 page summary of their comments for inclusion in the official meeting record. Members of the public may also submit written statements for the Committee’s review to Dr. Roberta White at rwhite@bu.edu.

Because the meeting is being held in a Government building, a photo I.D. must be presented as part of the clearance process; therefore, any person attending should allow an additional 15 minutes before the meeting begins. Any member of the public seeking additional information should contact Dr. White, Scientific Director, at (617) 638–4620 or Dr. Victor Kalasinsky, Designated Federal Officer, at (202) 443–5682.

Dated: May 19, 2015.

Rebecca Schiller,

Advisory Committee Management Officer.

[FR Doc. 2015–12428 Filed 5–21–15; 8:45 am]

BILLING CODE 8320–01–P

DEPARTMENT OF VETERANS AFFAIRS

Genomic Medicine Program Advisory Committee; Notice of Meeting

The Department of Veterans Affairs (VA) gives notice under the Federal Advisory Committee Act, 5 U.S.C. App. 2, that the Genomic Medicine Program Advisory Committee will meet on June 30, 2015, at the Department of Veterans Affairs, 810 Vermont Avenue NW., Washington, DC 20420, Room 230 (Sonny Montgomery Room). The meeting will convene at 9:00 a.m. and adjourn at 5:00 p.m. The meeting is open to the public.

The purpose of the Committee is to provide advice and make recommendations to the Secretary of Veterans Affairs on using genetic information to optimize medical care for Veterans and to enhance development of tests and treatments for diseases particularly relevant to Veterans.

The Committee will receive program updates and continue to provide insight into optimal ways for VA to incorporate genomic information into its health care program while applying appropriate ethical oversight and protecting the privacy of Veterans. The meeting focus will be on developing and implementing phenotyping and computational requirements for the Million Veteran Program. Public comments will be received at 3:30 p.m. and are limited to 5 minutes each. Individuals who speak are invited to submit a 1–2 page summary of their comments for inclusion in the official meeting record to Dr. Sumitra Muralidhar, Designated Federal Officer, 810 Vermont Avenue NW., Washington, DC 20420, or by email at sumitra.muralidhar@va.gov. Any member of the public seeking additional information should contact Dr. Muralidhar at (202) 443–5679.

Dated: May 19, 2015.

Rebecca Schiller,

Committee Management Officer.

[FR Doc. 2015–12511 Filed 5–21–15; 8:45 am]

BILLING CODE 8320–01–P